CA2402123A1 - Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose - Google Patents
Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose Download PDFInfo
- Publication number
- CA2402123A1 CA2402123A1 CA002402123A CA2402123A CA2402123A1 CA 2402123 A1 CA2402123 A1 CA 2402123A1 CA 002402123 A CA002402123 A CA 002402123A CA 2402123 A CA2402123 A CA 2402123A CA 2402123 A1 CA2402123 A1 CA 2402123A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- hydroxy
- alkyl
- pyridyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
Abstract
La présente invention concerne des composés pharmaceutiques utiles dans le traitement du diabète de type II. Ces composés présentent un avantage étant donné qu'ils sont rapidement métabolisés par les systèmes métaboliques de détoxication. Plus particulièrement, l'invention concerne des analogues de thiazolidinedione renfermant des esters dans la structure desdits composés. L'invention se rapporte également à des méthodes de traitement de troubles tels que le diabète. Ces méthodes consistent à administrer des compositions thérapeutiquement efficaces contenant des composés pouvant être métabolisés par un sérum ou des hydrolases et estérases intracellulaires. L'invention porte enfin sur les compositions de ces analogues de thiazolidinedione contenant des esters.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19914600P | 2000-04-24 | 2000-04-24 | |
US60/199,146 | 2000-04-24 | ||
US28198201P | 2001-04-06 | 2001-04-06 | |
US60/281,982 | 2001-04-06 | ||
PCT/US2001/013131 WO2001081328A2 (fr) | 2000-04-24 | 2001-04-24 | Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2402123A1 true CA2402123A1 (fr) | 2001-11-01 |
Family
ID=26894508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002402123A Abandoned CA2402123A1 (fr) | 2000-04-24 | 2001-04-24 | Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1276730A2 (fr) |
JP (1) | JP2003531200A (fr) |
AU (1) | AU2001259130A1 (fr) |
CA (1) | CA2402123A1 (fr) |
WO (1) | WO2001081328A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6768008B2 (en) * | 2000-04-24 | 2004-07-27 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
US6784199B2 (en) | 2000-09-21 | 2004-08-31 | Aryx Therapeutics | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals |
US6958355B2 (en) | 2000-04-24 | 2005-10-25 | Aryx Therapeutics, Inc. | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
US6680387B2 (en) | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
EP1537068A1 (fr) | 2002-07-19 | 2005-06-08 | Aryx Therapeutics | Substances et procedes pour le traitement de l'hypercholesterolemie |
FR2856060A1 (fr) * | 2003-06-12 | 2004-12-17 | Centre Nat Rech Scient | Groupement protecteur clivable par les albumines seriques |
US7566732B2 (en) | 2003-10-28 | 2009-07-28 | Rigel Pharmaceuticals, Inc. | Rhodanine compositions for use as antiviral agents |
NL2010010C2 (en) * | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
CN104306373B (zh) * | 2014-09-29 | 2017-08-08 | 中国科学院成都生物研究所 | 一种苯基恶唑类化合物在制备治疗癌症的药中的应用 |
IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2680512B1 (fr) * | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
NO302471B1 (no) * | 1991-12-26 | 1998-03-09 | Sankyo Co | Tiazolidinforbindelser og farmasöytisk preparat |
PT848004E (pt) * | 1995-07-31 | 2003-07-31 | Shionogi & Co | Derivados pirrolidina tendo actividade inibidora da fosfolipase a2 |
JPH09165371A (ja) * | 1995-10-09 | 1997-06-24 | Sankyo Co Ltd | 複素環化合物を含有する医薬 |
AU2231397A (en) * | 1996-03-08 | 1997-09-22 | Torii Pharmaceutical Co., Ltd. | Thiazolidine-2,4-dione derivatives |
JPH09301963A (ja) * | 1996-05-17 | 1997-11-25 | Kyorin Pharmaceut Co Ltd | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
AU6340600A (en) * | 1999-07-01 | 2001-01-22 | Geron Corporation | Telomerase inhibitors and methods of their use |
-
2001
- 2001-04-24 JP JP2001578420A patent/JP2003531200A/ja active Pending
- 2001-04-24 AU AU2001259130A patent/AU2001259130A1/en not_active Abandoned
- 2001-04-24 EP EP01932617A patent/EP1276730A2/fr not_active Withdrawn
- 2001-04-24 CA CA002402123A patent/CA2402123A1/fr not_active Abandoned
- 2001-04-24 WO PCT/US2001/013131 patent/WO2001081328A2/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2001259130A1 (en) | 2001-11-07 |
WO2001081328A3 (fr) | 2002-02-21 |
WO2001081328A2 (fr) | 2001-11-01 |
EP1276730A2 (fr) | 2003-01-22 |
JP2003531200A (ja) | 2003-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1040323C (zh) | 噻唑烷衍生物 | |
JPH10194970A (ja) | 置換チアゾリジンジオン誘導体を含む抗高脂血剤 | |
US5599826A (en) | Thiazolidinediones and drugs containing them | |
CS407991A3 (en) | Thiazolidinedione derivatives, their preparation and use | |
US6680387B2 (en) | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | |
TW400330B (en) | Novel thiazolidine-2, 4-dione, substitute, the manufacture method and the pharmaceutical compositions therefof | |
HUT65676A (en) | Process for producing oxa- and thiazolidinedione derivatives and pharmaceutical compositions containing them | |
CZ20021903A3 (cs) | Substituované deriváty oxazolu a thiazolu jakoľto HPPAR-alfa aktivátory | |
JPH0283384A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
CA2402123A1 (fr) | Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose | |
US6768008B2 (en) | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | |
WO2002046161A1 (fr) | Derives de l'acide carboxylique substitues | |
JPH0592960A (ja) | チアゾリジン−2,4−ジオン誘導体とその塩及び製造法 | |
EP0593348B1 (fr) | Dérivés de thiazolidin-2,4-dione, leur procédé de préparation et les compositions pharmaceutiques les contenant | |
US6958355B2 (en) | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | |
US20060047000A1 (en) | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | |
EP1430039A2 (fr) | Matieres et procedes pour le traitement de diabetes, de l'hyperlipidemie, de l'hypercholesterolemie, et de l'atherosclerose | |
JP2001518068A (ja) | 抗糖尿病、高脂血症、抗高血圧特性を有する新規なヘテロ環化合物、これらの製造方法及びこれらを含有する薬学的組成物 | |
AU2002327683A1 (en) | Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis | |
JPH02167224A (ja) | 抗脂血剤 | |
ZA200401945B (en) | Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis. | |
SK391691A3 (sk) | Tiazolidindiónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |